These findings on the role of IL-1 regardless of TNF-α activity in immune-mediated colitis could be related to the subgroup of patients with inflammatory bowel disease who are refractory to standard therapy with TNF-α blockers [110]. Here, IL1A is linked to inflammatory bowel disease.